JP2016534092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534092A5 JP2016534092A5 JP2016529755A JP2016529755A JP2016534092A5 JP 2016534092 A5 JP2016534092 A5 JP 2016534092A5 JP 2016529755 A JP2016529755 A JP 2016529755A JP 2016529755 A JP2016529755 A JP 2016529755A JP 2016534092 A5 JP2016534092 A5 JP 2016534092A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antigen
- cl2a
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/948,732 | 2013-07-23 | ||
| US13/948,732 US9028833B2 (en) | 2012-12-13 | 2013-07-23 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| PCT/US2014/034518 WO2015012904A2 (en) | 2012-12-13 | 2014-04-17 | Antibody-sn-38 immunoconjugates with a cl2a linker |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534092A JP2016534092A (ja) | 2016-11-04 |
| JP2016534092A5 true JP2016534092A5 (https=) | 2017-04-27 |
| JP6427789B2 JP6427789B2 (ja) | 2018-11-28 |
Family
ID=54873835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529755A Active JP6427789B2 (ja) | 2013-07-23 | 2014-04-17 | Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3024460B1 (https=) |
| JP (1) | JP6427789B2 (https=) |
| CN (2) | CN110075295A (https=) |
| AU (1) | AU2014293670B2 (https=) |
| CA (1) | CA2914438C (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214024A1 (en) * | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| WO2018031408A1 (en) * | 2016-08-11 | 2018-02-15 | Immunomedics, Inc. | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS |
| CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
| WO2018102212A1 (en) * | 2016-12-01 | 2018-06-07 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (immu-132) |
| SG11201910113PA (en) * | 2017-05-02 | 2019-11-28 | Nat Cancer Center Japan | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate |
| CN119241554A (zh) * | 2017-12-15 | 2025-01-03 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
| WO2019154120A1 (zh) * | 2018-02-11 | 2019-08-15 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
| AU2019247511B2 (en) | 2018-04-06 | 2025-10-16 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| EP3826673A4 (en) * | 2018-07-26 | 2022-03-09 | Tayu Huaxia Biotech Medical Group Co., Ltd. | COMPOSITIONS AND METHODS FOR IMAGING |
| EP3914610A1 (en) * | 2019-01-23 | 2021-12-01 | Millennium Pharmaceuticals, Inc. | Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors |
| CA3156803A1 (en) | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| KR20220113747A (ko) * | 2019-12-16 | 2022-08-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항 cea 항체-엑사테칸 유사체의 접합체 및 이의 약학적 용도 |
| JP7781064B2 (ja) | 2020-01-22 | 2025-12-05 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途 |
| CN111499685A (zh) * | 2020-03-30 | 2020-08-07 | 联宁（苏州）生物制药有限公司 | 具有马来酰亚胺连接头的抗体偶联药物中间体及其合成方法 |
| CN113527496B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| KR102349925B1 (ko) * | 2020-07-16 | 2022-01-12 | 주식회사 피노바이오 | Fl118 약물을 포함하는 화합물 및 이를 이용한 면역접합체 |
| WO2022078279A1 (zh) * | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| AU2022234045B2 (en) * | 2021-03-12 | 2025-05-29 | Japan Science And Technology Agency | Sn-38 derivative, nano-particles containing said derivative, medicine, and method for producing said nano-particles |
| CN113480651B (zh) * | 2021-07-19 | 2022-07-08 | 华东师范大学 | 一种靶向人cd133的纳米抗体及其制备方法和应用 |
| CA3225598A1 (en) | 2021-07-21 | 2023-01-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing anti-trop2 antibody drug conjugate and its application |
| WO2023198200A1 (zh) * | 2022-04-14 | 2023-10-19 | 苏州瑞博生物技术股份有限公司 | 缀合物与组合物及制备方法和用途 |
| CN114917222B (zh) * | 2022-04-29 | 2023-02-28 | 佛山病原微生物研究院 | 一种Ganetespib在制备用于抗腺病毒感染的药物中的用途 |
| CN116139267A (zh) * | 2023-01-28 | 2023-05-23 | 华中科技大学同济医学院附属同济医院 | 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 |
| CN119775347B (zh) * | 2024-12-31 | 2025-10-10 | 英科新创（苏州）生物科技有限公司 | 水溶性吖啶磺酰胺羧酸标记物、制备方法、其应用及试剂盒 |
| CN119775344B (zh) * | 2024-12-31 | 2025-08-26 | 英科新创（苏州）生物科技有限公司 | 水溶性吖啶磺酰胺衍生物、制备方法、其应用及试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028361D0 (en) * | 2000-11-21 | 2001-01-03 | Glaxo Group Ltd | Method of separating extra chromosomal dna from other cellular components |
| SE0104462D0 (sv) * | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Peptide purifcation (Peptidrening) |
| US8420086B2 (en) * | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| ES3000111T3 (en) * | 2009-02-13 | 2025-02-27 | Immunomedics Inc | Intermediates for preparing conjugates with an intracellularly-cleavable linkage |
| US9198972B2 (en) * | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| CN107753954A (zh) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
-
2014
- 2014-04-17 AU AU2014293670A patent/AU2014293670B2/en active Active
- 2014-04-17 JP JP2016529755A patent/JP6427789B2/ja active Active
- 2014-04-17 EP EP14828674.3A patent/EP3024460B1/en active Active
- 2014-04-17 CA CA2914438A patent/CA2914438C/en active Active
- 2014-04-17 CN CN201910347750.9A patent/CN110075295A/zh active Pending
- 2014-04-17 CN CN201480041766.2A patent/CN105407891A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534092A5 (https=) | ||
| JP2016520548A5 (https=) | ||
| JP2012500286A5 (https=) | ||
| JP2016513098A5 (https=) | ||
| US20200345854A1 (en) | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof | |
| JP7238030B2 (ja) | Ｔ細胞療法のために患者をコンディショニングする方法 | |
| JP2024153905A (ja) | Ｔ細胞療法のための診断方法 | |
| CN107735090B (zh) | 具有cl2a接头的抗体-sn-38免疫缀合物 | |
| JP2013503184A5 (https=) | ||
| US10669338B2 (en) | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 | |
| FI3903829T3 (fi) | Solunsisäisesti katkeavan sidoksen omaavia immunokonjugaatteja | |
| US20240252537A1 (en) | Precision molecular adaptor system for car-t immunotherapy | |
| JP2014514345A5 (https=) | ||
| US20180171003A1 (en) | Chimeric and Humanized Anti-Histone Antibodies | |
| JP2018522833A (ja) | キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療 | |
| WO2016172427A1 (en) | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells | |
| CN106029098A (zh) | 人源化rfb4抗cd22抗体 | |
| US10709701B2 (en) | Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | |
| JP2016534092A (ja) | Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体 | |
| US20170216447A1 (en) | Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers | |
| WO2018031408A1 (en) | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS | |
| Wang et al. | Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma | |
| WO2021022044A1 (en) | Depletion regimes for engineered t-cell or nk-cell therapy | |
| Suzuki et al. | Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma | |
| Xu et al. | Targeting diverse chimeric antigen receptor T cell-related targets in treatment of B-cell hematological malignancies: a review of long-term follow-up data |